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Although rarely elicited during natural human infec-
tion, the most broadly neutralizing antibodies
(BNAbs) against diverse human immunodeficiency
virus (HIV)-1 strains target the membrane-proximal
ectodomain region (MPER) of viral gp41. To gain
insight into MPER antigenicity, immunogenicity,
and viral function, we studied its structure in the lipid
environment by a combination of nuclear magnetic
resonance (NMR), electron paramagnetic resonance
(EPR), and surface plasmon resonance (SPR) tech-
niques. The analyses revealed a tilted N-terminal
a helix (aa 664–672) connected via a short hinge to
a flat C-terminal helical segment (675–683). This
metastable L-shaped structure is immersed in viral
membrane and, therefore, less accessible to immune
attack. Nonetheless, the 4E10 BNAb extracts buried
W672 and F673 after initial encounter with the sur-
face-embedded MPER. The data suggest how
BNAbs may perturb tryptophan residue-associated
viral fusion involving the mobile N-terminal MPER
segment and, given conservation of MPER se-
quences in HIV-1, HIV-2, and SIV, have important
implications for structure-guided vaccine design.INTRODUCTION
Since the acquired immunodeficiency syndrome (AIDS) was
recognized in 1981, an estimated 65 million infections and
25 million deaths have been ascribed to human immunodefi-
ciency virus-1 (HIV-1) (CDC, 2006). Preventative vaccination is
paramount to eliminate further global HIV-1 spread. Although
clinically valuable T cell-based vaccines may be developed,
B cell-stimulating vaccines capable of eliciting broadly neutraliz-52 Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc.ing antibodies (BNAbs) are essential (Douek et al., 2006; Letvin,
2006). Only BNAbs will prevent entry of the HIV retrovirus into
T cells to block viral replication as well as proviral integration
into the host genome, the latter establishing latent reservoirs of
disease (Han et al., 2007).
Unprecedented challenges to vaccine development arise from
virtually every aspect of HIV-1 biology including the extraordi-
nary viral sequence diversity of HIV proteins of which the virion
surface gp160 spike protein is an example (Korber et al.,
2001). gp160 is synthesized as a precursor, cleaved by furin-
like enzymes in the transgolgi into gp120 and gp41 subunits
that noncovalently associate, and assembled into heterotrimers.
gp120 binds to cell-surface CD4, then undergoes conforma-
tional change revealing a coreceptor attachment site (Feng
et al., 1996) whose ligation in turn induces structural rearrange-
ments within the transmembrane gp41 subunit to fuse viral and
host cell membranes (Chan et al., 1997). gp160 is extensively
glycosylated, displays prominent variable loop segments, exists
in several conformational states, and is proteolytically labile.
These features engender antibody responses primarily directed
against strain-specific sequences and including peptidic, non-
native HIV epitopes. In contrast, little viral cross-species neutral-
izing activities are elicited against conserved structural elements
that are shielded, difficult to access, or transient. Not surpris-
ingly, therefore, only a handful of human BNAbs have been iden-
tified to date (reviewed in Douek et al., 2006). Those BNAbs with
the greatest viral clade and strain breadth, including 2F5 and
4E10 (derived from immortalized B cells of HIV-1-infected indi-
viduals) and Z13e1 (selected from an affinity-matured phage-
display library using bone marrow RNA derived from a clade
B-infected individual), each targets the membrane-proximal ec-
todomain region (MPER) of gp41 (Nelson et al., 2007, and refer-
ences therein). The MPER lies at the base of gp41, immediately
proximal to the envelope’s transmembrane segment, and
although accessible to antibody, rarely, if ever, elicits BNAbs
during natural infection.
Detailed structural analysis of the MPER on a lipid environ-
ment approximating native conditions is, therefore, of great
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BNAb Capture of Kinked MPERimportance. In this regard, a recent cryoelectron microscopy
study (Zhu et al., 2006) has yielded a 3-dimensional structure
of the AIDS virus envelope spike, suggesting that each trimer
has independent legs that project obliquely from the trimer
head, like a tripod, and include the above BNAb region. Given
the low resolution achieved in that report and substantial differ-
ences with a second tomographic study (Zanetti et al., 2006), we
have determined at near atomic resolution the structure and dis-
position of the MPER on lipid membranes. In addition, we have
characterized MPER conformational changes upon 4E10 mono-
clonal antibody (mAb) binding by using complementary nuclear
magnetic resonance (NMR) and electron paramagnetic reso-
nance (EPR) biophysical methods. The findings provided a struc-
tural rationale both for how BNAbs function to block HIV-1
infection and for improving HIV vaccine design to elicit them.
RESULTS
The Micelle-Bound MPER Adopts an L-Shaped
Helical Structure
The HIV-1 MPER segment (amino acids 662–683) contains
a large number of hydrophobic residues, and hence can be sol-ubilized in aqueous solutions only in the presence of detergents
or lipid vesicles. NMR spectroscopic studies of the HXB2 MPER
in DPC micelles at pH 6.6 were carried out with isotopically
labeled peptide and multidimensional triple-resonance experi-
ments. The solution structure consisted of two discrete helical
segments with a central hinge, forming an L-shape (Figure 1A).
The N-terminal segment contained a 2-turn a helix from D664
to W672, whereas the C-terminal segment began with a 1-turn
a helix from I675 to L679 followed by a 310 helix from W680 to
K683. The characteristic a-helical 3-residue separated Ha to
Hb NOE and 4-residue separated Ha to HN NOE were clearly
missing for residues F673 and N674 in the hinge region
(Figure 1B). The flexibility of the hinge region resulted in an over-
all backbone rmsd of 0.59 A˚ when superimposed from residues
665 to 682 (see Table S1 available online). However, the individ-
ual N- or C-terminal segments converged well, with backbone
rmsd of 0.24 A˚ and 0.15 A˚, respectively (Figure 1C), excluding
the two N-terminal residues, E662 and L663, and the C-terminal
K683, which appeared to be extended and unstructured.
This structure is distinct from the straight a helix of an earlier
NMR model for the unlabeled MPER peptide in DPC micelle at
pH 3.5 (Schibli et al., 2001), which does not present a singleFigure 1. NMR Structure of the MPER in a DPC Micelle
(A) Stereo ribbon diagram of the MPER HxB2 peptide.
(B) Sequential plot of NMR constraints showing the a-helical pattern at the N-terminal andmixed 310 and a-helical pattern at the C-terminal end of MPER peptide.
This diagram is produced from CYANA (Guntert et al., 1992).
(C) Ensemble of 17 MPER NMR structure models superimposed by backbone atoms (colored in red) of the N-terminal segment (left in blue) or the C-terminal
segment (right in blue).
(D) Placement of theMPER peptide on the micelle surface (light yellow spheres at the bottom). The deep yellow sphere represents the lipid acyl-chain region. The
three well-conserved Trp residues important in virus-mediated fusion are shown in red, the three more variable solvent-exposed Asn residues are colored blue.Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc. 53
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BNAb Capture of Kinked MPERFigure 2. MPER Analysis by EPR: EPR Spectra, Accessibility Parameters, Immersion Depth, and Overall Topology
(A) EPR spectra of R1 side chains in MPER peptides bound to large unilamellar vesicles of POPC+POPG (4:1, w/w). Spectra were obtained in the absence (black
trace) and presence (red trace) of 4E10 antibody twice in excess to the peptide. Characteristic features of highly mobile spectra (E662R1, W670R1, andW678R1)
and highly immobile one (N677R1) are indicated by arrows and by an arrowhead, respectively. The vertical dotted lines indicate the approximate region of some
spectrawhere the immobile components are increasing upon 4E10 binding. Scanwidth (abscissa) was 100Gauss. Generation of the R1 side chain by the reaction
of the methanethiosulfonate nitroxide spin label with the cysteine residue is shown in the inset.
(B) Accessibility parametersP(O2) andP(NiEDDA) for R1 residues inMPER peptides bound to POPC+POPG vesicles as a function of residue number. Air oxygen
and 5 mM NiEDDA were used to measure the accessibility parameters, P(O2) (top) and P(NiEDDA) (bottom), respectively. The positions of P(O2) maxima and
corresponding positions in P(NiEDDA) are marked with vertical dotted lines.
(C) Immersion depth of the lipid-facing R1 residues of MPER bound to POPC+POPG (4:1, w/w) vesicles. Average values of 2–3 independent measurements are
reported with standard deviation. Depth values larger than 0 A˚ and between 0 and5 A˚ correspond to acyl chain region and headgroup region in the membrane,54 Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc.
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BNAb Capture of Kinked MPERmembrane-binding face. The kinked MPER structure with two
separate helical segments, on the other hand, uniquely pos-
sesses a hydrophobic membrane-binding face containing 4 of
the 5 Trp residues as well as the critical Phe 673 residue de-
scribed below, while 3 hydrophilic Asn residues within the
4E10 epitope are solvent exposed (Figure 1D; Figure S1). Taken
together, the L-shaped MPER structure on the membrane sur-
face is largely determined by the primary sequence distribution
of the hydrophobic amino acid residues.
Membrane Immersion Depths of Individual
MPER Residues
To experimentally determine the orientation of the MPER in the
membrane-bound state, we used the site-directed spin labeling
method (Hubbell et al., 1998) of electron paramagnetic reso-
nance (EPR) spectroscopy to study 22 synthetic MPER peptides
with spin labels at different residue positions (Figure 2A). The
accessibility values of the nitroxide spin-labeled side chains
(R1) to the relaxation agents, oxygen and NiEDDA, were mea-
sured by power saturation techniques (Altenbach et al., 1994)
for each spin-labeled peptide bound to a lipid bilayer (liposome)
consisting of POPC and POPG molecules. The plots of accessi-
bility parameters P(O2) and P(NiEDDA) (Figure 2B) showed that
the collision frequencies of the spin-labeled side chain R1 for the
relaxation agents oscillated as a function of sequence position.
Hence, the spin labels alternated between polar and nonpolar
environments. Interestingly, the two curves oscillated approxi-
mately in the same phase for residues 662R1–667R1 but in the
opposite phase (180) for residues 668R1–683R1. The periodic-
ity with local maxima (or minima) often occurred at every third or
fourth sequence position, suggesting that most residues were in
helical conformation in the presence of membrane. The mem-
brane immersion depths of MPER residues derived from the ratio
of the accessibility parameters were determined by EPR as
shown in Figure 2C. The residues L669R1, W670R1, W672R1,
F673R1, I675R1, W678R1, L679R1, Y681R1, I682R1, and
K683R1 were buried in the acyl chain region of the lipid bilayer
(depth > 0 A˚) while residues K665R1, W666R1, and T676R1 re-
sided close to the interface between the acyl chain region and
the lipid headgroup region. Residues D664R1, A667R1,
S668R1, and N674R1 were in the phospholipids headgroup
region (5 A˚ % depth % 0 A˚). Other residues such as L663R1,
N671R1, N677R1, and W680R1 were completely exposed to
the aqueous phase so that the immersion depths could not be
determined. The accessibility parameters and the immersion
depth data showed opposing solvent-exposed and mem-
brane-interacting faces, which were out of phase on the two
N- and C-terminal helices separated at residue N674 (Fig-
ure 2D), supporting the presence of a kink in the MPER helix.To provide a detailed structural basis for the EPR results, the
orientation of the MPER peptide relative to the lipid bilayer was
determined by fitting the membrane immersion-depth data by
computer simulations via simple helical models (Figure S2).
As depicted in Figure 2C, the N-terminal segment of the pep-
tide (residues 664–672) is in a-helical conformation with a tilting
angle of approximately 15 (upwards at the N terminus) relative
to the membrane surface (see also Figures 1D and 2F). The res-
idues 662–666 in the N-terminal helical segment, however,
didn’t fit well with the predicted depth pattern (not shown),
for which the accessibility parameters P(O2) and P(NiEDDA)
oscillate approximately in the same phase (Figure 2B). This dis-
crepancy may originate from either altered spin label conforma-
tions or from high exposure to the aqueous phase, as often ob-
served for helices on a soluble protein surface (Hubbell et al.,
1998). The C-terminal segment (residues 675–683) lies essen-
tially parallel to the membrane surface (tilt angle less than 5;
Figure 2C; Figure S2). The two helical segments connect
through a kink (Figure 2F) with angles ranging from 90 to
150 that were primarily defined by the peptide bonds between
F673 and N674 (Figure 1C). The pivot residue N674 resided in
the membrane headgroup region and pointed toward the aque-
ous phase. In contrast, F673 and I675, hydrogen-bonded within
the N- and C-terminal helices, respectively, anchored deeply
toward the hydrophobic region of the membrane (Figures 1D
and 2C).
The immersion depths of MPER R1 residues bound to vi-
rus membrane-like liposomes (DOPC/SM/DOPE/DOPG/CHOL
with the molar ratio of 34:7:16:10:33) showed essentially the
same results (Figure S3A), suggesting that the kinked structure
is a general feature even with a different lipid composition. In
addition, the NMR analyses of 15N-labeled MPER peptide in
DPC micelle and disc-like DHPC-DMPC bicelle showed similar
spectral patterns (Figure S3B). Because the MPER peptide
bound to the flat surfaces of lipid bicelle that resemble the
membranes of much larger lipid vesicles, the conformations
of the MPER peptides were expected to be similar in the mem-
brane systems (Chou et al., 2002) used in our EPR and NMR
studies. It is important to note that the L-shaped structure
was not caused by an adaptation of the peptide to the curva-
ture of the micelle surface. Instead, a large portion of the kink
region in the middle of the peptide was immersed deeply into
the micelle (Figure 1D), while the N-terminus projected away
from the micelle consistent with a trajectory connecting to the
extracellular part of gp41 in the full-length protein. Overall,
the N-terminal residues were predominantly exposed to the
aqueous phase, whereas the C-terminal residues leading to
the transmembrane helix were mostly immersed in the mem-
brane.respectively. The depths of lipid-facing R1 residues were fitted with membrane surface-bound helical models for the N-terminal (residues 667–673, dotted curve)
and C-terminal (residues 676–682, solid curve) helices as described in Figure S2.
(D) Helical wheel diagrams for N-terminal (residues 662–673) and C-terminal (residues 674–682) segments of the membrane-boundMPER. Open square, shaded
triangle, or filled circle represents a R1 residue exposed to aqueous phase, buried in the lipid headgroup region, or in the acyl chain region, respectively. The
topological location of the residue in parentheses was not determined.
(E) Membrane immersion depth for R1 residues in membrane-bound and 4E10-bound MPER peptide. The depths of the indicated R1 residues in the MPER
peptides bound to the POPC:POPG vesicles were measured in the presence of equimolar 4E10 antibody. Residues showing the largest depth change upon
4E10 binding are indicated with asterisks.
(F) A topological model of MPER peptide in the membrane (see also Figure S2). The tilted N-terminal helix (residues 664–672) is linked to the C-terminal helix
(residues 675–683) lying almost parallel to the membrane surface. Residues 673–674 serve as a linker.Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc. 55
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Variability within the Conserved MPER
The space-filling models of the MPER reveal how it is largely im-
mersed inamicelle (Figure3A).Remarkably, hydrophobic residues
buried in the lipid phase are the most conserved, in general,
whereas those polar residues exposed to the aqueous phase are
the most variable. As shown by Shannon entropy analysis of 975
HIV-1 sequences compiled fromM, O, N, and U groups and avail-
able M subgroups (Figure 3B; Figure S4), the variability of amino
acids at each of the 22 positions is limited, being among the least
variable of all 20 amino acid segments probed within the gp160
molecule (Figure 3B, insert). In particular, the 15 C-terminal resi-
dues of the MPER include only three positions, 671, 674, and 677
with valuesR 1. The other residues are either invariant or very re-
stricted, primarily representing dimorphic variants (Figure 3C).
Nonetheless, the implicationsofeven this limitedvariability for vac-
cine design, as discussed later, are remarkable because subtle
sequence alterations at 671 and/or 674 affect 4E10 and Z13e1Figure 3. SequenceConservationwithin the
MPER Segment of HIV-1 Envelope Proteins
(A) Space-filling model of the HxB2 MPER peptide
on a micelle (48 A˚ diameter).
(B) Shannon entropy is plotted for each residue
from 975 HIV-1 sequences with variability on the
y axis (0 = no variability at a given position; 4.322 =
all 20 amino acids permitted at that position).
The insert shows variability over the entire gp160
proteins from these same viral isolates. Open cir-
cles represent regions of conservation in gp160
comparable to that of the MPER segment (red
dot) and correspond to amino acid residues
(from left to right) 85–117, b1- a1 elements buried
within the inner domain; 187–222, V2- b3- b4
largely buried segments; 230–258, LA b6- b8,
LB, mostly buried within the inner domain; 512–
534, fusion peptide; 553–590, the N leucine zipper;
and 684–705, the TM segment abutting theMPER.
Analyses were performed with a window size of 20
residues and with the x axis showing amino acid
position of the window start. The residues that
are solvent accessible are shown in red.
(C) Graphical representation of amino acid pat-
terns within sequence alignments with WebLogo.
binding. Thus, it is evident that the hyper-
variability of the exposed residues as well
as the immersion of conserved hydropho-
bic residues in lipid facilitate evasion of
immune attack.
EPR Immersion Depth Changes
upon 4E10 mAb Binding
Unexpectedly, both EPR and NMR re-
sults showed that three hydrophobic
residues (W672, F673, and L679) critical
for neutralization of the HIV virus by
4E10 mAb (Zwick et al., 2005) were bur-
ied in the lipid phase. Only the key polar
T676 residue was in the headgroup re-56 Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc.gion. These findings suggest that the 4E10 mAb first attached
onto the membrane-bound MPER and subsequently induced
a major conformational change in the peptide, exposing the
complete epitope. To this end, we obtained EPR membrane im-
mersion depth data on spin-labeled MPER peptides that retain
affinity for 4E10 binding (Figure 2A; Figure S5) to confirm the
orientation of the MPER peptide in complex with 4E10 mAb
with respect to the membrane (Figure 2E). Spectral decompo-
sition of the spectra of 669R1, 679R1, 675R1, 678R1, and
681R1 in the presence of equimolar 4E10 (not shown), which
were essentially identical to those in Figure 2A, suggested
that the peptides were in equilibrium between the free and
bound state, obscuring accurate determination of the immer-
sion depths of the antibody-bound peptide in the membrane.
However, the change in the presence (Figure 2E) and absence
(Figure 2C) of 4E10 could be used as an indicator of either the
depth change or conformational change upon 4E10 binding for
these residues.
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4E10 antibody and theMPERpeptide sequence as shown bydata
derived from negative controls consisting of a 4E10-unreactive
mutant peptide W672A:F673A:N677R1 and a nonbinding control
IgG antibody (Figure S6). Notably, pronounced EPR spectral
changes were observed in N674R1, I675R1, N677R1, W678R1,
and Y681R1 (Figure 2A), at or near the C-terminal end of the
MPER peptide. On the other hand, the spin labeling at positions
W672, F673, and T676 completely abolished 4E10 antibody bind-
ing as determined by surface plasmon resonance (SPR) experi-
ments, and resulted in little or no EPR spectral changes in the
presence of 4E10 (Figure 2A; Figure S5). Overall, the trends in
the change in the immersion depth data implied that the N-termi-
nal segment was lifted up toward the aqueous phase whereas the
C-terminal segment was little affected (Figure 2E).MPERConformational Changes upon 4E10mAb Binding
To confirm those structural changes and assess conformational
alterations at all key binding residues, we investigated the MPER
peptide in complex with the 4E10 antigen-binding fragment (Fab)
in deuterated DPC micelles by NMR spectroscopy. The amide
chemical shift perturbations of the MPER residues upon 4E10
binding are shown in Figures 4A and 4B. Although all residues
that were measured manifest noticeable peak shifts, the residues
displaying the most significant changes (>0.5 ppm of normalized
chemical shifts) included the core 4E10 epitope residues WFNIT
(672–676), plus residues N671, N677, and L679, and the three
C-terminal residues Y681, I682, and K683. Results from NMR
cross-saturation experiment further identified those residues in di-
rectcontactwith the4E10antibody,becauseNMRmagnetizations
are transferred from the protonated methyl regions of 4E10 to theFigure 4. Conformational Change in MPER Induced by 4E10
(A) 15N-TROSY-HSQC spectrum containing free (blue) and Fab-bound HxB2 MPER peptide (red).
(B) Normalized (sqrt((DHcs)2 + (DNcs/5)2) in ppm) MPER amide chemical shift changes upon 4E10 binding.
(C) Relative signal reduction of amide peaks with 250 ms cross-saturation showing MPER residues involved in 4E10 interaction.
(D and E) Models for MPER peptide in complex with 4E10 antibody as viewed from the side (D) andmembrane face (E). The 4E10 light chain is colored yellow, and
the hydrophobic patches on 4E10 heavy chain are colored in green. The residues W672 to T676 essential for 4E10 binding are shown in blue, and residues N671
and W680 important for initial contacts with CDR3L and CDR3H, respectively, are shown in pink. In (D), the orientation of uncomplexed MPER is shown for
comparison.Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc. 57
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BNAb Capture of Kinked MPERnearby amides of the per-deuteratedMPERpeptide. The residues
in the MPER peptide that showed cross-saturation change (>5%
reduction) include the C-terminal segment 671–683 (Figure 4C).
The region of MPER peptide responsible for 4E10 binding,
therefore, was not restricted to the WFNIT core but comprised
a segment spanning 18 A˚, consistent with the width of the
4E10 Fab binding site. These results obtained for 4E10 binding
in the presence of membrane are in general agreement with
the recently published crystal structure of a soluble shorter
(671–683) MPER peptide in complex with the 4E10 antibody
(Cardoso et al., 2007).
Modeling 4E10 Interaction
with the Micelle-Bound MPER
The combined NMR and EPR data refined the existing model of
the 4E10 in complex with the full-length MPER peptide. Second-
ary structure information was obtained from the 13C chemical
shifts values of the per-deuterated MPER peptide in complex
with 4E10 (Figure S7 and Table S2). Upon binding, the hinge
region in the kinked MPER peptide had become part of the
C-terminal helix from W672 to K683, and residues W670 and
N671 adopted an extended, nonhelical conformation, in agree-
ment with the crystal structure (Cardoso et al., 2005, 2007).58 Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc.The N-terminal segment remained a-helical from residues
D664 to L669, permitting this segment to be appended to the
shorter MPER peptide from the crystal structure by overlapping
the residues N671 and W672 in our model (Figures 4D and 4E).
The NWFNIT segment made extensive interactions with anti-
body, with F673 swinging upward15 A˚ (end-to-end) and insert-
ing deeply into the 4E10 binding pocket. Additional contacts
were contributed by residues L679, W680, I682, and K683.
Among the four MPER residues (N671, N674, N677, and
W680) that were solvent accessible in the free form, N671 was
the most important for 4E10 interactions, by forming a hydrogen
bond with the 4E10 light chain (Cardoso et al., 2005, 2007).
N671 likely participated in the initial contact between the 4E10
antibody and the lipid-embedded segment prior to MPER
rearrangement as shown by the SPR data with a N671A mutant
(Figure 5A). Consistent with this notion, N671A contributed little,
if any, to 4E10 binding to MPER peptide in solution because
other core residues including W672 and F673 were exposed
(Brunel et al., 2006). Furthermore, mutation of N671 to naturally
occurring residues in other viral strains moderately (N671S) or
even more substantially (N671G, N671T, N671D) decreased
4E10 binding to the lipid-embedded MPER. Not surprisingly, en-
velopes from primary HIV-1 isolates with N671T mutation, forFigure 5. Assessment of BNAb with Membrane and MPER
(A) Critical role of N671 for 4E10 binding to MPER and liposomes by BIAcore. Control (HXB2) MPER and single amino acid variants are shown. 2F5 reactivity for
each variant was equivalent to the HXB2 control (not shown).
(B) ITC result of injecting 250 mM of MPER peptide with virion membrane-like liposome into 10 mM 4E10 Fab at 25C. The enthalpy change is 25.0 kcal/mole of
Fab molecule and the binding constant is 1.0 mM from fitting results, yielding a large positive entropic energy change of (TDS) = 16.9 kcal/mole.
(C) Binding of BNAbs 4E10, 2F5, and Z13e1 to synthetic virionmembrane-boundMPER (virion membrane+MPER) (black) and virionmembrane alone (red insert).
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core epitope show up to a 10-fold greater 4E10 resistance in
pseudovirus neutralization assays (Binley et al., 2004; Li et al.,
2005). Upon antibody binding, the N-terminal helix prior to
N671 remained relatively mobile, although partially confined by
the 4E10 light chain positioned above the membrane. Based
on the EPR results, the orientation of the 4E10 antibody was
such that it tilts away from theMPER peptide allowing the hydro-
phobic CDR2 (and potentially CDR3) loop of the heavy chain
fragment to set anchor in the viral membrane (Figures 4D and
4E). Collectively, 4E10 BNAb extracts its epitope from the viral
membrane in a multistep process as depicted in Movies S1
and S2.
Strong Lipid Binding Is Not an Essential
BNAb Requirement
To examine the energetics of 4E10 binding to the membrane-
embedded MPER, we performed ITC and SPR experiments by
using liposomes whose lipid constituents mimic those found in
HIV-1 virions (Bru¨gger et al., 2006). The enthalpy change by
ITC was determined to be 25 kcal/mole for the Fab form of
4E10, with a 1.0 mM Kd, suggesting a high entropic energy pen-
alty (Figure 5B). In addition, there was detectable monovalent
binding of 4E10 Fab with the virion membrane-like liposome in
the ITC experiment but too weak to quantitate. As a conse-
quence, we examined intact BNAb IgG binding by SPR. Consis-
tent with a prior study (Alam et al., 2007), the best global curve
fitting of 4E10 binding to the membrane-bound MPER involved
a two-step conformational change model with Kd of 10 nM.
Figure 5C compares the binding of 4E10 as well as Z13e1 and
2F5 to the virion membrane-embedded MPER versus virion
membrane alone. As shown, specific binding of Z13e1 and 2F5
to the MPER was comparable to that of 4E10, but little or no
direct binding to the membrane alone was observed. 4E10
mAb bound to the virion membranemimic but with amuch faster
off-rate and, consequently, a much weaker affinity (10 mM Kd).
Thus, strong membrane binding was not an essential BNAb
characteristic.
DISCUSSION
Biophysical studies demonstrate that the tryptophan-rich MPER
peptide addition to liposomes results in membrane instability at
high peptide concentrations (Lorizate et al., 2006). Tryptophan is
well known for its role in membrane destabilization (Popova
et al., 2002). Functional mutagenesis further highlights the im-
portant role of the MPER in HIV-1-mediated fusion (Dimitrov
et al., 2007; Lorizate et al., 2006; Munoz-Barroso et al., 1999;
Salzwedel et al., 1999; Sua´rez et al., 2000). Alanine substitutions
of all five MPER W residues [W(1-5)A] or the three within the
N-terminal helix (W666A, W670A, W672A) abrogates syncitium
formation as does deletion of the core hinge area (D671–677)
through inhibition of fusion pore expansion (Salzwedel et al.,
1999). By contrast, N-terminal D666–670 or C-terminal D678–
682 deletions reduce but do not eliminate syncitium formation,
and the W678A, W680A double mutant of the MPER C-terminal
helixW residues is without effect. The kink observed in theMPER
peptide structure may serve to allow independent movement of
the N-terminal segment containing the three W residues (W666,W670, and W672) critical for fusion (Figure 1D), relative to the
more fixed C-terminal segment. These movements appear to
be crucial for stable pore formation as suggested by earlier
site-directed mutation analysis of MPER residues (Munoz-Bar-
roso et al., 1999). In that study, scrambling the sequence shown
in our current study to comprise the hinge and several flanking
residues inhibited syncitium formation and macromolecular
dye transfer but not small-molecule transfer between enve-
lope-expressing cells and target cells. By modifying the mem-
brane orientation and/or positions of the tryptophans, it is likely
that 4E10 mediates its neutralizing activity, either by destabiliz-
ing the virus membrane and/or by impeding the sequence of
conformational changes within the MPER region necessary to
mediate virus-host cell fusion. Such neutralization is less likely
to be via disruption of the six-helix bundle formation because
other equally high-affinity mAbs targeting the C helix are not
neutralizing (Alam et al., 2007).
The fact that 4E10 (core epitope W672-T676), 2F5 (core
epitope D664-W666), and Z13e1 (core epitope W666-N677)
all crossblock each other and are broadly neutralizing HIV
mAbs further emphasizes the importance of this area (Barbato
et al., 2003). Based on the tripod-like model of the HIV-1 spike,
the MPER region is in a somewhat open configuration on the
‘‘foot’’ of ‘‘splayed leg’’ allowing access for these antibodies
(Zhu et al., 2006). Perhaps the limited copy number of enve-
lope protein on each HIV virion relative to orthologs on other
type I fusion viruses requires the MPER to augment fusion
pore formation, through stronger interaction with a larger mem-
brane area. The current L-shaped tryptophan-rich MPER struc-
ture supported this picture. The 8-residue MPER segment
C-terminal to the kink was likely to maintain a rigid association
with the transmembrane domain, and probably involved in
additional interaction with cholesterol in the lipid phase (Epand
et al., 2006).
This report revealed how an epitope buried in the membrane
can be recognized by an antibody. We demonstrated experi-
mentally that theMPER undergoesmajor conformational change
upon 4E10 binding in the lipid environment. Residue F673 swung
180 from the membrane interior to the antibody binding pocket
analogous to DNA helix bending and base-flipping of nucleo-
tides during DNA repair (Hollis et al., 2000). This dynamic pro-
cess is a unique phenomenon for antibody recognition. The
intrinsically flexible hinge and metastability of the MPER struc-
ture are important for this conformational change and could
conceivably be involved in facilitating the viral membrane fusion
process by disrupting the lipid layer of the opposing membrane
from the host cell. BNAbs 4E10 and Z13e1 straddle this hinge,
extracting key membrane-embedded residues into the anti-
body-combining site to achieve tight binding while dysregulating
the involvement of the N-terminal segment in membrane desta-
bilization.
Whereas the conformation of the 4E10 segment is presumed
to be largely helical in both prehairpin and intermediate states,
the conformational variability of the 2F5 segment may be greater
(Ofek et al., 2004, and references therein). It is possible that the
2F5 segment of MPERmay adopt a different conformation, if the
2F5 core or N-terminal adjacent sequence interacts with other
envelope ectodomain elements. Notably, the N-terminal part of
the 2F5 binding segment (662–663) and the hinge involvingImmunity 28, 52–63, January 2008 ª2008 Elsevier Inc. 59
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BNAb Capture of Kinked MPER4E10 and Z13e1 (673–674) appeared to be flexible in our struc-
ture. Similar to 4E10, 2F5 antibody may also extract its complete
epitope after initial contact with key exposed residues (662–664).
In addition, given that the gp41 6-helix bundle involves the 2F5
epitope sequence, 2F5 may also mediate neutralization by pre-
venting hairpin formation from a prehairpin gp41 configuration.
4E10 and Z13e1 may disrupt MPER pore formation, expansion,
or both processes.
That 4E10 and Z13e1 have comparable affinity for gp41 and
peptide derivatives therein, yet 4E10 is considerably more
biologically potent than Z13e1, argues that antibody affinity per
se is not the single determinant of neutralization (Nelson et al.,
2007). Consistent with this notion, the HIV-1 envelope trimer-
reactive 13H11 mAb maps N-terminal to 2F5 and, although
crossblocking the latter, is not a neutralizing antibody despite
comparable 9–12 nM affinity (Alam et al., 2007). Induction of
structural rearrangement of the MPER hinge region by anti-
bodies seems to be a key requirement for neutralization, assum-
ing equivalent accessibility to the segment. Consequently, it is
possible that the broadly neutralizing antibodies act by targeting
the flexible region so as to restrict the movements of the MPER
peptide relative to other parts of gp41 during fusion-associated
conformational changes.
The observation that 2F5 and 4E10mAbsmanifest reactivity to
lipid autoantigens such as cardiolipin has raised the possibility
that the scarcity of broadly neutralizing antibodies in humans
may result from their elimination through natural B cell tolerance
mechanisms to self-antigens (Alam et al., 2007; Haynes et al.,
2005). The current structural data suggest that the lipid specific-
ity of those BNAbs is a consequence of the membrane-embed-
ded environment of the MPER against which they are elicited.
The majority of binding energy is dependent on the unique
MPER viral sequence, making it evident that viral-specific bind-
ing to the MPER rather than broad autoreactivity should be
engendered from MPER-related immunogens. On the other
hand, membrane lipid components may modulate MPER inter-
action with the membrane and/or with antibody, explaining, at
least in part, the discrepancy in 4E10 antibody neutralization
efficiency for the same virus produced in 293T cells versus
peripheral blood mononuclear cells (Binley et al., 2004).
The binding of MPER peptide by 4E10 antibody may involve
three steps as eluded to earlier. First, 4E10 antibody interacts
with membrane and encounters the membrane-bound MPER
peptide. The initial interaction likely involves N671, and possibly
W680, thereby orienting the peptide with respect to the antibody
binding pocket. In the second step, changes in the local peptide
environment introduced by the hydrophobic regions of the anti-
body cause rearrangement ofmultiple side chains in the C-termi-
nal segment. Especially, F673 may be rotated into the antibody
binding pocket, concomitant with the backbone angle changes
of F673 and N674 removing the kink in the middle of the peptide.
In the third step, the insertion of F673 and W672 deep into the
4E10 binding pocket changes the backbone angles of W672,
N671, and W670, bending the N-terminal segment in the
opposite direction to avoid steric clashes with the 4E10 light
chain.
In addition to being the target of existing monoclonal BNAbs
with greatest breadth (Binley et al., 2004; Nelson et al., 2007),
two immunogenicity studies underscore the importance of defin-60 Immunity 28, 52–63, January 2008 ª2008 Elsevier Inc.ing the MPER structure on a lipid environment for purposes of
vaccine design. First, it has been observed that no HIV-1 BNAbs
were elicited after immunization of animals with a truncated pre-
fusion-envelope protein lacking the MPER (Qiao et al., 2005).
Second, immunization of guinea pigs with recombinant HIV-1
virus-like particles (VLP) including the MPER-elicited high-titer
VLP antibodies, but these were directed away from the MPER,
instead showing specificity for the C-terminal helix segment of
gp41 and without neutralizing activity (Kim et al., 2007). The
lipid-embedded ‘‘stealth’’ feature of the MPER explains the
lack of immune responses to the MPER as compared to more
accessible immunodominant cluster I and II regions of gp41
(Xu et al., 1991). Thus, antibodies directed against the MPER
4E10 and 2F5 epitopes are rarely, if ever, found during natural
infection and are extremely difficult to elicit through immuniza-
tion because of the nonimmunodominance of this region (Kim
et al., 2007; Yuste et al., 2006). Instead, non-neutralizing cluster
I-II antibodies develop during HIV-1 infection.
Attempts to engineer enforcedMPER helices, either engrafted
on proteins (Law et al., 2007) or chemically stabilized by non-nat-
ural peptide bonds (Brunel et al., 2006; Cardoso et al., 2007),
represent elegant approaches. However, the conformational
changes noted within the lipid-embedded MPER upon 4E10
antibody binding to membranes dispelled the notion of a static
‘‘neutralizing’’ versus ‘‘non-neutralizing’’ MPER face for immuno-
gen design. Vaccine design based on targeting postconforma-
tional change epitopes could misguide the immune system.
Our structural data and bioinformatics analyses suggested that
an appropriate solution may be the use of lipid-coated nanopar-
ticles to present membrane-embedded MPER segments in their
L-shaped native conformation displaying exposed 671, 674, and
677 variants and invariant residue 680 to the immune system.
Such a strategy avoids exposure to exosomal proteins incorpo-
rated into VLPs or other misdirecting epitopes on chimeric pro-
teins, instead allowing the isolated MPER to assume a native
configuration in the lipid environment. By eliciting antibodies
that contact the invariant exposed W680, in addition to the three
polar exposed residues, it should be possible to engender high-
affinity antibody interactions without a need to recruit buried res-
idues, thereby avoiding entropic penalty. Our prediction is that
such antibodies will be able to recognize native HIV-1 epitopes
in themembrane environment, and bind theMPERwith sufficient
affinities to impede its fusogenic activity. Aside from providing
impetus for future vaccination strategies, these data emphasize
that BNAbs are notable for their site-specific binding to a func-
tionally important envelope segment.EXPERIMENTAL PROCEDURES
Materials
Phospholipids 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1,2-
dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), 1,2-dioleoyl-sn-
glycero-3-[phospho-rac-(1-glycerol)] (DOPG), and egg sphingomyelin (SM)
dissolved in chloroform and cholesterol (CHOL) in powder were purchased
from Avanti Polar Lipids. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (POPG),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphotempocholine (PC tempo), 1-pal-
mitoyl-2-stearoyl(5-doxyl)-sn-glycero-3-phosphocholine (5-doxyl PC), 1-pal-
mitoyl-2-stearoyl(7-doxyl)-sn-glycero-3-phosphocholine (7-doxyl PC), 1-
palmitoyl-2-stearoyl(10-doxyl)-sn-glycero-3-phosphocholine (10-doxyl PC),
Immunity
BNAb Capture of Kinked MPERand 1-palmitoyl-2-stearoyl(12-doxyl)-sn-glycero-3-phosphocholine (12-doxyl
PC) were purchased from Avanti Polar Lipids, Inc. N-tempoylpalmitamide
was synthesized asdescribed (Shin andHubbell, 1992). Dodecyl phosphatidyl-
choline (DPC) for micelle, 1,2-diheptanoyl-sn-glycero-3-phosphocholine
(DHPC) and 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) for bicelle
were purchased from Avanti Polar Lipids (Alabaster, AL). Deuterated (d38-)
DPC was purchased from Cambridge Isotope Laboratories (Andover, MA).
The MPER segment 662–683 of HXB2 (ELDKWASLWNWFNITNWLWYIK),
the ADA strain (ALDKWASLWNWFDISNWLWYIK) or mutant variants were
expressed as aGB1-MPER fusion protein in E. coli. Each peptide was released
from the fusion protein via cyanogen bromide (CNBr) cleavage and purified by
high-performance liquid chromatography (HPLC) to greater than 95% homo-
geneity. For spin-labeling experiments, the MPER segment 662–683 of HXB2
with a single cysteine substitution at various positions were synthesized and
desalted at the Tufts Peptide Synthesis Core. The N and C termini of all the
peptides were modified by acetylation and amidation, respectively.
EPR Spectroscopy
EPR spectra were obtained on a Bruker EMX spectrometer with a Bruker High
Sensitivity resonator at room temperature. All spectra were recorded at 2 mW
incident microwave power with a field modulation of 1.0–2.0 G at 100 kHz. For
power saturation experiments, NiEDDA was synthesized as described (Alten-
bach et al., 1994; Oh et al., 2000). In order to measure the accessibility param-
eters, P, of O2 and NiEDDA, power saturation experiments were carried out
with a loop-gap resonator (JAGMAR, Krakow, Poland) (Farahbakhsh et al.,
1992; Oh et al., 2000; Shin and Hubbell, 1992). The source of oxygen gas
was air supplied in-house and the concentration of NiEDDA was 5 mM. N2
gas was used to purge O2 when necessary. In order to measure the immersion
depths of membrane-inserted spin-labeled residues (Supplemental Experi-
mental Procedures), air O2 and 50 or 100 mM NiEDDA were used as collision
reagents. The range of the incident microwave power was 0.4 to 100 mW for
power saturation experiments. Power saturation data were analyzed with the
R program (version 1.5.1) (Ihaka and Gentleman, 1996). Depth calibration
curves were determined with the large unilamellar vesicles consisting of
POPC/POPG (4:1, w/w) containing spin-labeled lipids (see Supplemental
Data) (Altenbach et al., 1994; Farahbakhsh et al., 1992) in the presence and
absence of 4E10 antibody at 800:1 molar ratio of total phosphate to antibody.
In order to determine the number of spin labels attached to peptides, EPR
spectra were taken after liberating the spin labels from the peptide molecules
by incubating the labeled peptides with 100 mM tris-(2-carboxyethyl)phos-
phine (Molecular Probes, Inc.). The amount of spin label was calculated by
double integration of the EPR spectra with 3-carboxy-proxyl (Sigma-Aldrich)
as a standard.
SPR Measurements
BIAcore experiments were carried out with a BIAcore 3000 with the Pioneer L1
sensor chip composed of alkyl chains covalently linked to a dextran-coated
gold surface (BIAcore AB, Uppsala, Sweden) at 25C. The running buffer
was 20 mM HEPES containing 0.15 M NaCl (pH 7.4) (HBS-N). The BIAcore
instrument was cleaned extensively and left running overnight with Milli-Q
water to remove trace amounts of detergent. The LUV (30 ml, 5 mM) was
applied to the sensor chip surface at a flow rate of 3 ml/min, and the liposomes
were captured on the surface of the sensor chip and provided a supported lipid
bilayer. To remove any multilamellar structures from the lipid surface, sodium
hydroxide (20 ml, 25 mM) was injected at a flow rate of 100 ml/min, which re-
sulted in a stable baseline corresponding to the immobilized liposome bilayer
membrane with response units (RU) of 8,000–11,000.
Peptide solutions (0.7 mM) were prepared by dissolving in running buffer
right before injection and the solution (60 ml) was injected over the lipid surface
at a flow rate of 5 ml/min. Antibody solution (20 mg/ml) was passed over
peptide-liposome complex for 3 min at a flow rate of 5 ml/min. Because the
peptide-lipid interactions are very hydrophobic, the regeneration of the lipo-
some surface was not possible. The immobilized liposomes were therefore
completely removed with an injection of 40 mM CHAPS (25 ml) at a flow rate
of 5 ml/min, and each peptide injection was performed on a freshly prepared
liposome surface.
For analysis of antibody binding to spin-labeled, membrane-bound MPER
peptides, a volume of 30 ml of POPC/POPG (4:1, w/w) LUVs (10.5 mM phos-phate) in HBS-N was layered onto an L1 Sensor Chip and followed by spin-la-
beled peptide and antibody injection as described above at a rate of 3 ml/min.
The wild-type and mutant peptide with 672A:673A double alanine substitution
mutations were prepared as described in Expression and purification of MPER
segments.
ITC Experiments
Samples for ITC experiments were prepared in HBS-N buffer. 20 injections of
15 ml liposome-MPER peptidemixture were delivered to 1.35ml of 10 mM4E10
Fab. 4E10 Fab was prepared with the Pierce Fab digestion kit according to
the manufacturer’s recommendations. Data were acquired at 25C with
a MicroCal ITC instrument and analyzed with the software Microcal Origin
(Northampton, MA).
NMR Spectroscopy and Structure Modeling
Samples for NMR experiments were prepared by codissolving lyophilized
MPER peptides with regular or deuterated DPC and adjusted to pH 6.6. All
NMR experiments were carried out at 35C on spectrometers equipped with
cryogenic probes. The data for backbone assignment of MPER peptide in
DPC micelle were acquired with a Varian Inova 600 MHz spectrometer. The
3D 15N-NOESY (60 ms mixing time) and 2D NOESY (80 ms mixing time, in
D2O) data were acquired with Bruker 750 MHz and 600 MHz spectrometers,
respectively. The TROSY data of MPER peptide in complex with 4E10 Fab
were acquired with a Bruker 900 MHz spectrometer. The cross-saturation
experiment (Shimada, 2005) was performed on a Bruker 600 MHz spectrom-
eter in an interleaved fashion with 250 ms WURST 1H saturation pulses with
2.3 ppm bandwidth irradiating at 0 ppm (methyl region) and 40 ppm (empty
region) for alternating FIDs.
Data were processed with the software PROSA (Guntert et al., 1992) and an-
alyzedwith the software CARA (Keller, 2004). Chemical shift assignmentswere
carried out with conventional NMR techniques (Ferentz and Wagner, 2000).
The preliminary structures were calculated with the software CYANA (Guntert,
2004) and the final structures by XPLOR-NIH (Brunger, 1992; Schwieters et al.,
2003). NMR constraints and structural statistics are listed in Table S1.
The antibody-bound MPER peptide was modeled based on the X-ray crys-
tallographic structure of peptide mimics in complex with 4E10 Fab (PDB code:
2FX7, 1TZG), the solution NMR structure of the free peptide as well as struc-
tural information obtained from the TROSY NMR experiments (Pervushin,
2000). The secondary structures were confirmed from TALOS (Cornilescu
et al., 1999) analysis of the chemical shift data (Table S2).
Supplemental Data
Seven figures, two tables, twomovies, and Experimental Procedures are avail-
able at http://www.immunity.com/cgi/content/full/28/1/52/DC1/.
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